Pyxis Oncology, Inc.
PYXS
$1.04
-$0.005-0.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -27.05% | -28.94% | -12.82% | -16.50% | -17.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.61% | -20.44% | -21.57% | -28.81% | -34.87% |
| Operating Income | 18.47% | 36.39% | 36.97% | 43.09% | 34.87% |
| Income Before Tax | -7.73% | 39.17% | 40.15% | 46.76% | 38.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.80% | 39.17% | 40.15% | 46.76% | 38.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.80% | 39.17% | 40.15% | 46.76% | 38.87% |
| EBIT | 18.47% | 36.39% | 36.97% | 43.09% | 34.87% |
| EBITDA | 20.26% | 38.61% | 39.11% | 45.26% | 36.07% |
| EPS Basic | 31.46% | 58.91% | 55.80% | 56.94% | 48.80% |
| Normalized Basic EPS | 47.91% | 58.90% | 55.80% | 56.95% | 48.80% |
| EPS Diluted | 31.46% | 58.91% | 55.80% | 56.94% | 48.80% |
| Normalized Diluted EPS | 47.91% | 58.90% | 55.80% | 56.95% | 48.80% |
| Average Basic Shares Outstanding | 46.50% | 44.78% | 40.04% | 29.83% | 20.75% |
| Average Diluted Shares Outstanding | 46.50% | 44.78% | 40.04% | 29.83% | 20.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |